cervomed.com (CRVO) - Enterprise Value to EBITDA Ratio
CervoMed Inc. (CRVO) specializes in the treatment of dementia, yet faces threats due to a limited development pipeline and a high burn rate. The price indicator on the EV/EBITDA chart is fixed at 0.00. High brand authority among physicians confirms the value of their approaches. Therapy safety is ensured through a strict temperature regime during the transportation of components.
CRVO (cervomed.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- business book valuation details:
- business debt structure and liquidity details:
- business earnings and investment ratios data:
CRVO - Company Profit|Projected Future Earnings CervoMed Inc.|CRVO - Price to Earnings Ratio|Projected Price to Earnings CervoMed Inc.|CRVO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple CervoMed Corporation|CRVO - Operating profit before deduction of amortization|Earnings per share for the last twelve months CervoMed|CRVO - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months cervomed.com|CRVO - Earnings per share growth in current year|Net earnings per share growth forecast for next year CervoMed Inc.
- revenue and sales details:
Fundamental company valuation:CervoMed Inc (CRVO)
The resilience of CervoMed Inc. (CRVO) is driven by successes in clinical trials for dementia drugs, rendering the company's historical EV/EBITDA trend an indicator of market expectations for future breakthroughs. This multiple compares the total enterprise value, including debt obligations, against operating profit, allowing investors to identify fundamental asset undervaluation relative to industry norms or hidden financial leverage risks.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|RGC: Enterprise Value to EBITDA Ratio|AXSM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to EBITDA Ratio Supernus Corp (SUPN)|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|BHVN: Enterprise Value to Operating Income Before Depreciation|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|AVXL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Enterprise Value to Operating Income Before Depreciation PRTA (Prothena Corporation PLC)|EV/EBITDA Multiple ALEC|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|Omeros - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio neurogene.com (NGNE)|AC Immune SA - EV/EBITDA Multiple|Voyager Therapeutics Inc (VYGR) - Enterprise Value to EBITDA Ratio|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TVGN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACOG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|IKT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|ASRT: Enterprise Value to Operating Income Before Depreciation|Coya - EV/EBITDA Multiple|Company Value to EBITDA Vistagen Therapeutics|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|Acumen Pharmaceuticals Inc. (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|CLNN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|JUNS - Company Value to EBITDA|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|ANVS - Enterprise Value to EBITDA Ratio|Grace Tx - EV/EBITDA Multiple|Company Value to EBITDA Firefly Neuro|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics Ltd. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio RVPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MTVA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP - Enterprise Value to EBITDA Ratio|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Athira Pharma Inc|ADXN: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ALZN|Enterprise Value to EBITDA Ratio CYCN|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Total Company Value to Operating Income Before Depreciation Ratio cortigent.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI: Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics, Inc. - EV/EBITDA Multiple|chromocell.com (CHRO) - Enterprise Value to EBITDA Ratio|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Marinus Pharma (MRNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Synaptogenix Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vigil Neuroscience|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
